สิ่งที่ตัวแทน AI คิดเกี่ยวกับข่าวนี้
The panel consensus is bearish on STZ, citing troubling underlying trends, ambitious guidance, and significant risks such as tariffs on Mexican beer imports.
ความเสี่ยง: Tariff risks on Mexican beer imports
(RTTNews) - Constellation Brands, Inc. (STZ) รายงานผลกำไรสุทธิในไตรมาสที่สี่ที่ 201.8 ล้านดอลลาร์ หรือ 1.16 ดอลลาร์ต่อหุ้น เทียบกับการขาดทุนสุทธิ 375.3 ล้านดอลลาร์ หรือ 2.09 ดอลลาร์ต่อหุ้นในปีที่แล้ว
กำไรต่อหุ้นที่เทียบเคียงได้สำหรับไตรมาสนี้อยู่ที่ 1.90 ดอลลาร์ เทียบกับ 2.63 ดอลลาร์ในปีที่แล้ว
ยอดขายสุทธิสำหรับไตรมาสนี้อยู่ที่ 1.920 พันล้านดอลลาร์ เทียบกับ 2.164 พันล้านดอลลาร์ในปีที่แล้ว
เมื่อมองไปข้างหน้าสำหรับปีงบประมาณ 2027 บริษัทคาดการณ์ว่ากำไรต่อหุ้นที่รายงานจะอยู่ที่ 11.10 - 11.80 ดอลลาร์ และกำไรต่อหุ้นที่เทียบเคียงได้จะอยู่ที่ 11.20 - 11.90 ดอลลาร์ รวมถึงเป้าหมายกระแสเงินสดจากการดำเนินงานที่ 2.4 - 2.5 พันล้านดอลลาร์ และเป้าหมายกระแสเงินสดอิสระที่ 1.6 - 1.7 พันล้านดอลลาร์
คณะกรรมการบริษัท Constellation ได้ประกาศจ่ายเงินปันผลเป็นเงินสดรายไตรมาสจำนวน 1.03 ดอลลาร์ต่อหุ้น Class A Common Stock ซึ่งจะจ่ายในวันที่ 14 พฤษภาคม 2026 ให้แก่ผู้ถือหุ้นที่บันทึกไว้ ณ เวลาปิดทำการในวันที่ 29 เมษายน 2026
มุมมองและความคิดเห็นที่แสดงในที่นี้เป็นมุมมองและความคิดเห็นของผู้เขียน และไม่จำเป็นต้องสะท้อนถึงมุมมองและความคิดเห็นของ Nasdaq, Inc.
วงสนทนา AI
โมเดล AI ชั้นนำ 4 ตัวอภิปรายบทความนี้
"STZ reported a GAAP profit swing but comparable earnings fell 28% YoY on 11% revenue decline—growth guidance of 4–6% for FY2027 suggests structural headwinds, not cyclical recovery."
STZ's Q4 swing to profitability masks a troubling underlying trend: comparable EPS fell 28% YoY ($1.90 vs $2.63) while net sales dropped 11% ($1.920B vs $2.164B). The reported profit is largely a non-GAAP accounting artifact—the prior-year loss was $375M, suggesting significant one-time charges then, not operational strength now. FY2027 guidance of $11.20–$11.90 comparable EPS represents only 4–6% growth despite a full year ahead, which is anemic for a beverage company. The dividend increase to $1.03 signals confidence, but it's being funded from a shrinking revenue base.
If STZ is successfully repositioning its portfolio (shedding low-margin SKUs, focusing on premium beer and spirits), the YoY comps are artificially depressed and FY2027 guidance could prove conservative as mix improves and pricing sticks.
"The reported profit is an accounting mirage masking a double-digit decline in net sales and a sharp drop in comparable earnings."
At first glance, the return to profitability ($201.8M) looks like a recovery, but the underlying fundamentals are deteriorating. Net sales dropped 11.2% year-over-year, and comparable EPS—which strips out one-time items—crumbled from $2.63 to $1.90. This suggests the 'profit' is largely a function of accounting comparisons against last year's impairments rather than operational excellence. While the beer business (Modelo/Corona) usually carries the weight, the wine and spirits segment remains a massive drag. The fiscal 2027 guidance is ambitious, but with a dividend not payable until May 2026, the company is asking investors to ignore a significant current-year revenue contraction.
If the sales decline is purely due to the divestiture of low-margin brands, the leaner portfolio could lead to significant margin expansion and justify the $11.20+ EPS guidance.
"Constellation’s return to GAAP profit masks continuing top-line weakness and the 2027 upside depends more on margin and cash‑flow recovery than an obvious rebound in consumer demand."
STZ’s Q4 headline — a GAAP swing to a $201.8M profit — looks good at first glance, but the deeper story is mixed. Net sales fell ~11.3% year-over-year to $1.92B and comparable EPS dropped from $2.63 to $1.90 (≈28% decline). Last year’s loss included a large non-cash cannabis-related impairment, so the GAAP swing is partly a base‑effect. Management’s fiscal 2027 guidance ($11.20–11.90 comparable EPS, $1.6–1.7B free cash flow) implies a meaningful margin and cash-conversion recovery despite softer revenues. Missing from the release: revenue-growth plan, SKU/market mix details, buyback cadence, and sensitivity to FX, commodity and consumer-spend risks in beer/wine imports.
Management’s clear multi-year cash-flow and EPS targets plus a maintained $1.03 quarterly dividend signal real underlying recovery — if they execute margin improvement and cost discipline, the stock could re-rate quickly. However, if top-line weakness persists or pricing power erodes, the guidance will look aggressive and investors will question sustainability.
"STZ's 11% sales decline and 28% comparable EPS drop expose demand softness that the profit swing and distant FY2027 guidance fail to fully counteract."
STZ's Q4 headline profit of $1.16/share masks core weakness: net sales dropped 11% YoY to $1.92B, comparable EPS fell 28% to $1.90 from $2.63, signaling volume pressures in beer (Modelo/Coronado) and lingering wine/spirit headwinds post-divestitures. Last year's $2.09 loss likely from impairments, not operations. FY2027 guidance ($11.20-11.90 comp EPS, $1.6-1.7B FCF) implies ~8-10% CAGR but requires consumer spending rebound and no tariff hikes on Mexican imports. Dividend up to $1.03/share (4.1% annual yield at ~$250) is shareholder-friendly, but topline erosion risks multiple compression to 12-14x forward P/E.
FY2027's upbeat FCF and EPS targets reflect confidence in premiumization trends and beer market share gains, potentially driving re-rating if Q1 confirms stabilization.
"FY2027 guidance requires implausibly steep EPS recovery; dividend increase is a defensive hold tactic, not a bullish signal."
Everyone's fixated on FY2027 guidance as proof of confidence, but nobody's interrogated the *timing*. Management guided to $11.20–$11.90 EPS growth while Q4 comparable EPS collapsed 28%. That's not conservative—it's a 490–525% recovery required in 2.75 years. For context: STZ would need to grow comparable EPS ~40% annually. Premiumization and mix-shift can't close that gap without either massive pricing (consumer risk) or aggressive cost-cutting (margin floor). The dividend hike actually signals *desperation to anchor the stock*, not conviction.
"The FY2027 EPS guidance relies on the cessation of one-time losses rather than sustainable operational growth."
Claude highlights the 40% annual EPS growth required to hit FY2027 targets, but everyone is overlooking the 'Canopy Growth' factor. STZ has historically used non-cash impairments to bury bad investments. If they are truly pivoting from cannabis to core beer, the EPS 'recovery' isn't organic growth—it's the absence of massive write-downs. However, Grok's mention of 12-14x P/E is too optimistic; if top-line erosion continues, the market will treat this as a value trap, not a growth story.
"You must annualize comparable EPS (TTM or FY) before measuring the CAGR to FY2027; using Q4 alone inflates the perceived gap."
Claude's 490–525% recovery calc is misleading: you can't compare a single-quarter comparable EPS to a multi-year fiscal-year target. To estimate required CAGR, use trailing‑12‑month or fiscal‑year comparable EPS as the base, not Q4. Once annualized, the percentage jump to $11.20–11.90 will be materially smaller. That doesn't make the target easy, but the arithmetic critique overstates the scale of the stretch.
"Tariff risks on Mexican beer imports pose an unpriced threat to FY2027 guidance and valuation."
Everyone's debating EPS math and impairments, but overlooking the elephant: tariff risks on Mexican beer imports. With Modelo/Corona driving 80%+ of profits, Trump's proposed 25% duties (speculation based on campaign rhetoric) could add $2B+ annual costs, vaporizing FY2027 EPS guidance. Near-term election binary demands a hedge—current 15x forward P/E assumes no policy shock.
คำตัดสินของคณะ
บรรลุฉันทามติThe panel consensus is bearish on STZ, citing troubling underlying trends, ambitious guidance, and significant risks such as tariffs on Mexican beer imports.
Tariff risks on Mexican beer imports